BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Wednesday, April 29, 2026
Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 14, 2004

View Archived Issues

Activity of fidarestat in diabetic neuropathy evaluated in mice and humans

Read More

Schering AG names new derma company Intendis

Read More

Bonefos accepted for priority review

Read More

Oscient launches Factive for lower respiratory tract infections

Read More

Roche and Structural GenomiX form antiviral alliance

Read More

New FAAH inhibitors and their use in pain and other disorders

Read More

Aventis presents novel PTP inhibitors and their use

Read More

Novel GPa inhibitors prepared and tested by Aventis researchers

Read More

New gamma-secretase inhibitors designed by Sanofi-Synthelabo team

Read More

Pfizer claims new 5-HT7 receptor modulators for depression, anxiety, etc.

Read More

New alpha2, alpha3 and/or alpha5-selective GABA-A receptor ligands claimed by Merck

Read More

Novel 11beta-HSD-1 inhibitors in early development at Novartis

Read More

New PYY analogues and their use in body weight disorders

Read More

Promising p38alpha inhibitor against the progression of rheumatoid arthritis

Read More

Orally active PDE4 inhibitor for the treatment of inflammatory respiratory diseases

Read More

Antiobesity treatment with melanin-concentrating hormone receptor-1 antagonist

Read More

Enrollment completed in phase III anidulafungin study

Read More

Multikine lowers cholesterol in clinical studies

Read More

H3 Pharma and DSM sign manufacturing agreement for SC-1

Read More

New dosage strengths of Avandamet approved in E.U.

Read More

IR-103 enters first clinical testing

Read More

Positive phase IIb results for harkoseride in epilepsy

Read More

Vivus initiates phase III study of Alista

Read More

Eurand to develop modified-release lercanidipine for Recordati

Read More

TheraQuest Biosciences discovers analgesic synergy with narcotics

Read More

Strakan and ProSkelia complete merger, renamed ProStrakan

Read More

Rivastigmine reported to slow cognitive decline in AD regardless of disease severity

Read More

Clinical trials assess the effects of magnesium sulfate in asthma and COPD

Read More

Tobacco smoke and immunosuppression in lung transplantation

Read More

Coating medical devices with key protein to prevent infection

Read More

FDA advisory committee recommends further data for Exanta approval

Read More

Aminoguanidine, ALT-711 renoprotective in hyperlipidemia/diabetes model

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for April 28, 2026.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for April 28, 2026
  • Silhouette of head, brain

    Plasticity, properly parsed, provides psychiatric platform

    BioWorld
    If Benjamin Braddock, of The Graduate fame, were a young neuroscientist in the 21st century instead of a liberal arts graduate in 1967, the advice he received...
  • Roche identifies new TREM2 agonists

    BioWorld Science
    F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have prepared and tested new compounds acting as triggering receptor expressed on myeloid cells 2 (TREM2)...
  • Three red darts on target

    Sun Pharma to acquire Merck spinoff Organon for $11.75B

    BioWorld
    Sun Pharmaceuticals Industries Ltd. will pay $11.75 billion cash to acquire Organon & Co. The transaction is expected to close in early 2027. The addition of...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing